This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenspan, S. L. Search for Related Content PubMed PubMed Citation Articles by Greenspan, S. L. Related Collections Calcium and Bone Metabolism Endocrine Oncology

Approach to the Prostate Cancer Patient with Bone Disease

University of Pittsburgh School of Medicine, Clinical and Translational Research Center, Osteoporosis Prevention and Treatment Center, Pittsburgh, Pennsylvania 15213

Address all correspondence and requests for reprints to: Susan L. Greenspan, M.D., University of Pittsburgh School of Medicine, Clinical and Translational Research Center, Osteoporosis Prevention and Treatment Center, 3471 Fifth Avenue, Pittsburgh, Pennsylvania 15213. E-mail: greenspans{at}dom.pitt.edu.

Prostate cancer is the most common visceral malignancy in men. Androgen deprivation therapy (ADT) is commonly used in patients with nonmetastatic prostate cancer and is associated with significant bone loss and fractures. The greatest bone loss occurs during initiation of ADT. Men should have assessment of skeletal integrity with bone mineral density examination by dual x-ray absorptiometry of the hip and spine. Men with fragility fractures or osteoporosis by bone density should be considered for bisphosphonate therapy. Men with low bone mass may need antiresorptive therapy, depending on other risk factors. Men with a normal bone mineral density should be followed up closely with bone densitometry while on ADT. All men should receive preventive measures with calcium (1200 mg daily in divided doses), vitamin D (800–1000 IU/d), and weight-bearing exercise. Men should be evaluated for additional secondary causes of bone loss including vitamin D insufficiency. Guidelines are needed for androgen-induced bone loss screening and treatment.

This article has been cited by other articles:

				S. L. Greenspan, J. B. Nelson, D. L. Trump, J. M. Wagner, M. E. Miller, S. Perera, and N. M. Resnick Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy J. Clin. Oncol., September 20, 2008; 26(27): 4426 - 4434. [Abstract] [Full Text] [PDF]

				H. G. Skinner and G. G. Schwartz Serum Calcium and Incident and Fatal Prostate Cancer in the National Health and Nutrition Examination Survey Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2302 - 2305. [Abstract] [Full Text] [PDF]